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Background and the purpose of the study: The febrile reaction is a complex response involving immunologic
and other physiologic systems. Antipyretics are commonly used in critically ill patients with fever. We investigated
the inflammatory responses following application of antipyretic therapy in febrile critically ill patients with Systemic
Inflammatory Response Syndrome (SIRS).
Patients and methods: In a prospective, randomized controlled study, critically ill patients with fever (T≥ 38.3°C),
SIRS diagnosed within 24 hours of Intensive Care Unit (ICU) admission and Acute Physiology and Chronic Health
Evaluation II (APACHE II) score ≥10 were randomized into two groups. Upon appearance of fever, one group
received intravenous paracetamol 650 mg every 6 hours for 10 days and other group received no treatment unless
temperature reached 40°C. Body temperature, Acute Physiology and Chronic Health Evaluation II (APACHE II) and
Sepsis-related Organ Failure Assessment (SOFA) scores, length of ICU stay, ICU mortality and infectious
complications were recorded. Levels of Interleukin-1 alpha (IL-1α), IL-6, IL-10, Tumour Necrosis Factor alpha (TNFα)
and High-Sensitive C-Reactive Protein (HS-CRP) were assessed at baseline and 2, 6 and 24 hours after intervention.
Results and discussion: During a period of 15-month screening, 20 patients met the criteria and randomized to
the control or paracetamol group. Body temperature decreased significantly in the paracetamol group (p = 0.004)
and control group (p = 0.001) after 24 hours, but there was no significant difference between two groups at this
time point (p = 0.649). Levels of IL-6 and IL-10 decreased significantly (p = 0.025 and p = 0.047, respectively) in the
paracetamol group at 24 hours but this was not of statistical significance in control group. No patterns over time in
each group or differences across two groups were found for HS-CRP, TNFα, and IL-1α (p > 0.05). There were no
differences regarding ICU length of stay, mortality and infectious complications between both groups.
Conclusion: These results suggest that antipyretic therapy may not be indicated in all ICU patients. Allowing fever
to take its natural course does not appear to have detrimental effects on critically ill patients with SIRS and may
avoid unnecessary expenses.
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Fever, defined as an increase in body temperature above
38.3°C (100.4°F), is among the most frequently detected
abnormal physical signs in critically ill patients related
either to SIRS or infections [1,2]. Fever is associated with
increased length of stay in general ICU patients and
poorer outcomes in certain patient groups such as
those with Traumatic Brain Injury (TBI), Subarachnoid
Hemorrhage (SAH) or pancreatitis [3,4]. Two prospect-
ive, observational studies of fever in the ICU suggested
that fever is deleterious for ICU patients [5,6].
On the other hand, febrile response involves activation
of immunologic, endocrinologic and other physiologic
systems [7,8]. The response is generally beneficial, be-
cause such responses promote clearance of pathogenic
microorganisms and hence improve outcome during
infections [9].
Despite the contradictory effects of fever, antipyretic
therapy including administration of antipyretic medica-
tions or application of external cooling is usually initiated
[10]. The common justification for such therapy includes
improved patient comfort, reduction in cardiovascular
stress and avoidance of increased oxygen consumption
[11].
Induction of fever is mediated by the release of pyro-
genic cytokines such as TNFα, IL-1, IL-6 and interferons
into the bloodstream in response to exogenous pyrogens.
These cytokines play pivotal roles in inflammation and ac-
tivation of the immune response. Extravagant activation of
immune system with these inflammatory biomarkers can
result in disastrous consequences like vascular collapse,
shock and death [12-14]. Also increased temperature is
known to induce changes in many of the effector cells of
the immune response which could be harmful [15]. On
the other hand, fever induces production of Heat Shock
Proteins (HSPs) which subsequently reduces the levels of
TNFα, IL-1, IL-6 and IL-10 [16]. Antipyretic therapy
might mitigate the harmful effects of pyrogenic cytokines;
however it may prevent the beneficial effects of fever.
The purpose of this study was to evaluate the effects
of antipyretic therapy on inflammatory biomarkers in fe-
brile critically ill patients with SIRS. We hypothesized
that optimal application of antipyretic therapy improves
clinical outcomes in critically ill patients with fever
and SIRS.
Methods
This prospective randomized clinical trial was con-
ducted in the 12-bed general ICU of Sina Hospital
affiliated to Tehran University of Medical Sciences
(TUMS) in Tehran, Iran. The study received ethical ap-
proval from ethic committee of TUMS (Code No.:
9755) and written informed consent was obtained from
patients or their kin.During 15 months, all patients admitted to the ICU
were screened for study eligibility and randomly assigned
to one of two treatment groups. Computer-generated ran-
dom number was utilized for randomization. Inclusion
criteria were age≥ 18 years, an APACHE II score≥ 10, a
core temperature≥ 38.3°C accompanied by at least one
other SIRS criterion (defined as the following conditions:
heart rate > 90 beat/min, respiratory rate >20 breath/min
or PaCO2< 32 mmHg, white blood cells (WBC) > 12,000
cell/mm3, or < 4000 cell/mm3, or >10% immature [band]
cells) diagnosed during the first 24 hours of ICU admis-
sion. Exclusion criteria were acute renal failure (defined as
ClCr < 50 ml/min or U/O<0.5 ml/kg/h), liver dysfunction
(defined as the presence of hepatic cirrhosis, hepatic en-
cephalopathy or concentration of serum transaminases
greater than third times the upper limit of normal range),
SIRS diagnosed after 24 hours of ICU admission, history
of seizure, stroke, or any acute brain injury (e.g. TBI), ma-
lignant hyperthermia (T≥ 41°C), heat stroke, or Neurolep-
tic Malignant Syndrome (NMS), Ischemic Heart Disease
(IHD), tympanic membrane inflammation or otitis (since
body temperature is measured by infrared tympanic
thermometer), age <18 years and pregnant or breast-
feeding women.
Patients body temperatures were measured routinely
(every 3 hours) by an infrared tympanic thermometer
(Genius 2, USA). Upon appearance of fever, patients
were randomized to receive a slow infusion of intraven-
ous paracetamol (ApotelW, Uni Pharma, Greece) 650 mg
every 6 hours for 10 days in the treatment group while
in the control group, no antipyretic was administered
unless the temperature reached 40°C.
Monitoring parameters including O2 saturation, non
invasive blood pressure and central venous pressure, re-
spiratory rate, heart rate and intake and output of each
patient were recorded in the ICU flow sheets every 3
hours. Laboratory data including serum creatinine, Blood
Urea Nitrogen (BUN), hemoglobin, platelet and WBC
counts, activated Partial Thromboplastin Time (aPTT),
Prothrombin Time (PT), International Normalization
Ratio (INR), Erythrocyte Sedimentation Rate (ESR), albu-
min, sodium and potassium were also collected routinely
and upon necessity.
Each group received standard treatments including early
resuscitation within the first 6 hours of admission, appro-
priate diagnostic studies to ascertain causative organisms
before starting antibiotics, early administration of broad-
spectrum antibiotic therapy and reassessment of antibiotic
therapy with microbiologic tests and clinical data to nar-
row coverage. Volume resuscitation was achieved with
0.9% normal saline and albumin for a target Central Ven-
ous Pressure (CVP) of 8–12 mmHg. After adequate fluid
resuscitation, Mean Arterial Pressure (MAP) was kept be-
tween 60–90 mmHg, using vasopressors or inotrops if
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tain SaO2 > 95%, PaO2 > 60 mmHg and PaCO2 between 38
and 42 mmHg and appropriate analgesia and sedation
were provided for all patients. Insulin treatment was
administered to maintain glucose at < 200 mg/dl and
standard prophylactic measures were made for Deep Vein
Thrombosis (DVT) and Stress-Related Mucosal Damage
(SRMD).
Measurements
On the appearance of fever (hour 0) as a baseline, 2, 6,
and 24 hours post administration of paracetamol or no
antipyretic, venous blood samples were collected and
centrifuged at 1500 rpm for 15 minutes to remove cells
and cellular debris. The plasma was stored at −80°C
until the time of analysis. Levels of IL-1α, IL-6, IL-10,
TNFα and High-Sensitive C-Reactive Protein (HS-CRP)
were measured by commercially available enzyme-linked
immunosorbent assay (ELISA) kits (Bender Med Sys-
tems Inc., Vienna, Austria) according to manufacturer’s
instruction.
Sepsis-related Organ Failure Assessment (SOFA) score
and APACHE II score were measured daily for 10 days.
Length of ICU stay, ICU mortality, infectious complica-
tions and ventilator free days were recorded for all
patients.
Statistical analysis
Data are presented as mean ± standard error of mean.
To assess differences between the treatment groups at
each time point, the unpaired t test and the Mann–
Whitney test were used for parametric and nonpara-
metric variables, respectively. To assess differences be-
tween the time points in each treatment group,
repeated-measure one-way analysis of variance and non-
parametric analysis of variance (Friedman test) were
used to analyze changes in temperature and levels of
biomarkers. For the analysis of changes in variables withTable 1 Demographic characteristics of febrile patients
No antipyretic (n = 10
Age (year) 45.4 ± 6.67
Male/Female (No.) 6/4
APACHE II score 14.5 ± 1.00
SOFA score 5.4 ± 0.89
Tmax (°C) 38.81 ± 0.15
Mean of all temperatures (°C) 37.39 ± 0.14
Proven infection (No.) 5
ICU stay (day) 22.1 ± 3.43
Ventilator free days 33.3%
ICU mortality (No.) 3
p values <0.05 considered as significant. Data shown are mean± SE.2 time points (at baseline and 24 hours after), the paired
t test and the Wilcoxon rank sum test were used for
parametric and nonparametric variables, respectively.
The Fisher exact test was used to compare ratios be-
tween the 2 groups. All tests reported a 2-sided P value
with the level of significance set at 0.05.Results
General characteristics and body temperature
Between November, 2009 and February, 2011, 307 con-
secutive patients admitted to the ICU were screened and
20 met criteria for enrollment. Ten patients were rando-
mized to the control (no antipyretic) group and ten were
randomized to the paracetamol group.
The patients in each group were similar at baseline
regarding to age, gender, admission APACHE II and
SOFA score (Table 1). The average of all temperatures,
maximum temperature of all days, incidence rates of in-
fection (based on culture results), ICU length of stay,
ventilator free days, and ICU mortality were similar for
both groups.
The mean temperature decreased from 38.53 ± 0.08°C
to 37.46 ± 0.27°C (p = 0.004) in the treatment group and
from 38.62 ± 0.10°C to 37.37 ± 0.19°C (p = 0.001) in the
group without treatment at 24 hours (Figure 1). There
was no significant difference between two groups at this
time point (p = 0.649).
In our study intravenous paracetamol was well toler-
ated and no adverse effects regarding hepatotoxicity
–defined as levels of serum transaminases more than
third times the upper limit of normal range- were seen
in the treatment arm.Biomarkers assay
HS-CRP, IL-6 and IL-10 were highly elevated at baseline
and after 24 hours compared to normal concentrations
in two groups (Table 2).) Paracetamol (n = 10) p Value
49.5 ± 5.37 0.638
8/2 >0.05
14.9 ± 0.81 0.760
5.7 ± 1.20 0.843
38.83 ± 0.14 0.921
37.32 ± 0.18 0.762
4 >0.05
23.6 ± 4.32 0.789
35.7% 0.887
2 >0.05
Figure 1 Evolution of body temperature after paracetamol and no antipyretic treatment. Temperature well decreased in both groups after
24 hours (p < 0.05); but differences between two groups were not significant (p > 0.05). Figure shows mean temperatures ± SE.
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p = 0.037, respectively) in the paracetamol group at 24
hours but this was not of statistical significance in
control group (p = 0.889 and p = 0.878, respectively)
(Figures 2 and 3). However; at none of the time points
(0, 2, 6, and 24 h), there were no significant differences
between two groups (p > 0.05). No patterns over time in
each group or differences across two groups were found
for HS-CRP, TNFα, and IL-1α (p > 0.05).
Discussion
The present findings show that intravenous paracetamol
has no effect on fever and fever is resolved spontan-
eously without any intervention. Meanwhile treatment
of fever had no effect on length of ICU stay, incidence
rates of infection, mechanical ventilation dependency
and ICU mortality.
Fever is characterized by an elevation of body
temperature above normal variation due to an altered
hypothalamic set point. It has been shown that fever is
the product of endogenous pyrogens such as IL-1, IL-6
and TNFα [1]. There are still contradictory results about
beneficial or deleterious effects of fever. Considerable
amount of evidence shows that fever is an importantTable 2 Cytokine concentrations at baseline and 24 hours aft
No Antipyretic
Baseline t24 p
HS-CRP (mg/l) 11.69 ± 3.00 12.18 ± 3.40 0
TNFα (pg/ml) 5.16 ± 1.35 4.7 ± 0.62 0
IL-1α (pg/ml) 1.33 ± 0.63 1.27 ± 0.56 0
IL-6 (pg/ml) 62.33 ± 22.58 47.96 ± 18.74 0
IL-10 (pg/ml) 73.85 ± 35.76 58 ± 20.39 0
p values <0.05 considered as significant.
Data shown are mean ± SE.defense mechanism which contributes to the host’s abil-
ity to resist infections [1,17]. Temperature in the range
of the usual fever renders host defenses more active and
many pathogens more susceptible to these defenses [18].
On the other hand, potential adverse consequences of
fever such as increased metabolic demand may be ex-
tremely detrimental in certain patient’s population such
as those with neurologic and cardiovascular conditions
and make intervention necessary [2-4]. Two prospective,
observational studies in critically ill febrile patients
showed that fever is harmful for ICU patients. Circiu-
maru et al. [5] in a research on 100 patients found that
prolonged fever more than five days was related to
poorer outcome. Barie et al. [6] studied 626 febrile
patients and found that peak temperature was the most
powerful predictor of mortality.
Laupland et al. [3] in another retrospective cohort
study on 20466 patients showed that the incidence of
fever was higher in trauma/neuro patients, males,
younger patients and those with admission APACHE II
score less than 25. They also found that fever alone
(T ≥ 38.3°C) was not associated with increased risk of
death (13% vs. 12%; p = 0.08), but that high fever
(T ≥ 39.5°C) was associated with significantly increaseder intervention (t24)
Paracetamol
Value Baseline t24 P Value
.753 15.26 ± 3.70 12.13 ± 3.46 0.236
.285 4.68 ± 1.32 3.8 ± 1.05 0.401
.674 1.57 ± 1.26 1.17 ± 0.87 0.397
.889 88.79 ± 23.15 30.12 ± 8.20 0.025
.878 93.64 ± 46.60 48.36 ± 23.35 0.037
Figure 2 Interleukin 6 levels in paracetamol and no antipyretic groups. IL-6 decreased significantly in paracetamol group (p < 0.05); but not
in the no treatment arm. However, differences between two groups were not significant (p > 0.05). Figure shows mean IL-6 levels ± SE.
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none of these studies evaluated the effects of antipyretic
therapy on patients’ outcome.
However results of randomized trials with antipyretic
show that treatment of fever may not be indicated in all
ICU patients. In a randomized prospective study of anti-
pyretics in 38 surgical ICU patients without neuro-
trauma or severe hypoxemia and with SIRS and fever,
Gozzoli et al. [19] found no significant differences in re-
currence of fever, incidence of infection, antibiotic ther-
apy, ICU or hospital length of stay, and mortality. Our
results also confirmed that antipyretic therapy had no ef-
fect on patients’ outcome. In another prospective study,
Schulman et al. [20] randomized 82 critically ill patients
into aggressive (44 patients) or permissive (38 patients)
groups. The aggressive group received acetaminophen
650 mg every 6 h for temperature of > 38.5°C. The per-
missive group received no treatment for temperature ofFigure 3 Interleukin 10 levels in paracetamol and no antipyretic grou
not in the no treatment arm. However, differences between two groups w>38.5°C, but instead had treatment initiated at
temperature of >40°C. No significant differences regard-
ing incidence rates of infection were noted between two
groups. There were seven deaths in the aggressive group
and only one death in the permissive group (p = 0.06).
The trial was ceased after the first interim analysis due
to the mortality difference and it was thought that ag-
gressively treating fever in critically ill patients may lead
to a higher mortality.
Gazzoli et al. [21] in an open-label randomized trial in
30 mechanically ventilated surgical ICU patients, investi-
gated the metabolic, hemodynamic and inflammatory
responses of pharmacologic (intravenous propacetamol
or metamizol) and physical therapy (external cooling) to
reduce body temperature. They concluded that both
treatments (pharmacologic and external cooling) equally
reduced temperature. The inflammatory responses (IL-6,
IL-8, TNFα and CRP) were not influenced by threeps. IL-10 decreased significantly in paracetamol group (p < 0.05); but
ere not significant (p > 0.05). Figure shows mean IL-10 levels ± SE.
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over time in the metamizol arm. Similarly in our study
levels of HS-CRP and cytokines (IL-1α and TNFα) were
not statistically different between two groups at any of
the time points during intervention, but levels of IL-6
and IL-10 decreased significantly in paracetamol group
at 24 hours and this was not of significant difference
in group without treatment. However, no differences
regarding these cytokines were seen between two arms.
Some studies indicate the correlation between early
levels of IL-6 and IL-10 and Injury Severity Score (ISS),
development of Multi Organ Dysfunction Syndrome
(MODS) and mortality in polytraumatized ICU patients
[22-25]. Since IL-10 is an anti-inflammatory cytokine,
increased levels could be attributed to a compensatory
reaction to hamper deleterious overinflammation. In our
trial, paracetamol significantly reduced both levels of IL-
6 and 10, so its effect on inflammatory response remains
unclear. Despite the fact that pyrogenic cytokines medi-
ate the potential role in febrile response and physiologic
abnormalities due to certain infections [15,26,27], in our
study along with previous reports [22,23], interventions
to decrease the level of these biomarkers was not benefi-
cial in patients’ outcome.Conclusion
Fever is triggered by the release of various cytokines,
notably IL-1, IL-6 and TNFα which in turn can affect the
immune response and defense mechanisms in a complex
way. Antipyretics might mitigate the harmful effects of
pyrogenic cytokines; however they may also hurdle the
beneficial effects of fever. The present study, in addition
to previous reports, suggests that antipyretic therapy
may not be justified in all ICU patients, especially those
without malignant hyperthermia, neurotrauma or other
acute neurological disorders. Until sufficient data from
large randomized clinical trials is available, allowing
fever to take its natural pathway does not seem to have
detrimental effects on all critically ill patients with SIRS
and may avoid unnecessary expenses.Competing interests
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